NEW YORK--(BUSINESS WIRE)--July 11, 2006--Acusphere, Inc (Nasdaq: ACUS - News) today, in conjunction with the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference, announced that it produced a full commercial scale development batch of AI-700 at the Company’s commercial manufacturing facility in Tewksbury, Massachusetts. This batch met all of its pre-defined target specifications. AI-700 is an ultrasound contrast agent in development for the detection of coronary heart disease, the leading cause of death in the United States, and is the Company’s leading product candidate, currently in Phase 3 clinical trials.
